A Cost-Effectiveness Analysis of Docetaxel in the Second-Line Treatment of Non-Small Cell Lung Cancer

By Holmes J.  

PharmacoEconomics, Vol. 22, Iss. 9, 2004-01 ,pp. : 581-589

Adis International

Access to resources Recommend Favorite

Cost-effectiveness of Erlotinib versus Docetaxel for Second-line Treatment of Advanced Non-small-cell Lung Cancer in the United Kingdom

By Lewis G   Peake M   Aultman R   Gyldmark M   Morlotti L   Creeden J   de la Orden M  

The Journal of International Medical Research, Vol. 38, Iss. 1, 2010-01 ,pp. : 9-21

Field House Publishing

Access to resources Recommend Favorite

Non–Small Cell Lung Cancer

By  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 6, Iss. 3, 2008-03 ,pp. : 228-228

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Quality of Life and Utility in Patients with Non-Small Cell Lung Cancer

By Trippoli S.   Vaiani M.   Lucioni C.   Messori A.  

PharmacoEconomics, Vol. 19, Iss. 8, 2001-01 ,pp. : 855-863

Adis International

Access to resources Recommend Favorite

The role of gefitinib in the management of Asian patients with non-small cell lung cancer

By Chang Alex Y  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 3, 2008-03 ,pp. : 401-411

Informa Healthcare

Access to resources Recommend Favorite